GSK China gets record fine and top executives suspended sentencesBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5799 (Published 22 September 2014) Cite this as: BMJ 2014;349:g5799
- Jane Parry
- 1Hong Kong
GlaxoSmithKline’s China operation has been fined ¥3bn (£299m; €379m; $488m) after being found guilty of bribery by the Changsha Intermediate People’s Court in Hunan province. In the closed door trial, which concluded on 19 September, five executives of GSK China Investment Company were also given suspended jail sentences of between two and four years.
The former manager, Mark Reilly, was given a four year suspended sentence and will be deported. The other four were Chinese nationals: the former human resources director, Zhang Guowei, former vice president, Liang Hong, former legal affairs director, Zhao Hongyan, and former business development manager, Huang Hong, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial